Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Ruberg

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|October 10, 2024
Reply to 'Bayesian approaches in drug development: continuing the virtuous cycle'Stephen J Ruberg
Journal of Biopharmaceutical Statistics|September 24, 2015
Making what's advanced today routine tomorrowStephen J Ruberg
Pharmaceutical Statistics|March 3, 2021
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: The hardest problem there isStephen J Ruberg
Clinical Pharmacology and Therapeutics|August 5, 2020
Détente: A Practical Understanding of P values and Bayesian Posterior ProbabilitiesStephen J Ruberg
Clinical Pharmacology and Therapeutics|September 12, 2017
Considerations for Evaluating Treatment Effects From Randomized Clinical TrialsStephen J Ruberg, Mouna Akacha
Pharmaceutical Statistics|September 4, 2008
ICH-E9 reflections and considerationsFrank W Rockhold, Stephen J Ruberg
Pharmaceutical Statistics|January 14, 2021
Implementation of tripartite estimands using adherence causal estimators under the causal inference frameworkYongming Qu, Junxiang Luo, Stephen J Ruberg
Clinical Trials (London, England)|July 30, 2010
The mean does not mean as much anymore: finding sub-groups for tailored therapeuticsStephen J Ruberg, Lei Chen, Yanping Wang
Pharmaceutical Statistics|December 20, 2021
Estimating the treatment effect for adherers using multiple imputationJunxiang Luo, Stephen J Ruberg, Yongming Qu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Raising the bar of efficacy for drug approval requires an understanding of patient diversityMarc L Berger, Stephen Eck, Stephen J Ruberg
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|October 10, 2024
Reply to 'Bayesian approaches in drug development: continuing the virtuous cycle'Stephen J Ruberg
Journal of Biopharmaceutical Statistics|September 24, 2015
Making what's advanced today routine tomorrowStephen J Ruberg
Pharmaceutical Statistics|March 3, 2021
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: The hardest problem there isStephen J Ruberg
Clinical Pharmacology and Therapeutics|August 5, 2020
Détente: A Practical Understanding of P values and Bayesian Posterior ProbabilitiesStephen J Ruberg
Clinical Pharmacology and Therapeutics|September 12, 2017
Considerations for Evaluating Treatment Effects From Randomized Clinical TrialsStephen J Ruberg, Mouna Akacha
Pharmaceutical Statistics|September 4, 2008
ICH-E9 reflections and considerationsFrank W Rockhold, Stephen J Ruberg
Pharmaceutical Statistics|January 14, 2021
Implementation of tripartite estimands using adherence causal estimators under the causal inference frameworkYongming Qu, Junxiang Luo, Stephen J Ruberg
Clinical Trials (London, England)|July 30, 2010
The mean does not mean as much anymore: finding sub-groups for tailored therapeuticsStephen J Ruberg, Lei Chen, Yanping Wang
Pharmaceutical Statistics|December 20, 2021
Estimating the treatment effect for adherers using multiple imputationJunxiang Luo, Stephen J Ruberg, Yongming Qu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Raising the bar of efficacy for drug approval requires an understanding of patient diversityMarc L Berger, Stephen Eck, Stephen J Ruberg
Pageof 2